Denali Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 294.12 million compared to USD 52.48 million a year ago. Net income was USD 183.38 million compared to net loss of USD 58.79 million a year ago. Basic earnings per share from continuing operations was USD 1.34 compared to basic loss per share from continuing operations of USD 0.48 a year ago. Diluted earnings per share from continuing operations was USD 1.3 compared to diluted loss per share from continuing operations of USD 0.48 a year ago.
For the six months, revenue was USD 329.26 million compared to USD 94.62 million a year ago. Net income was USD 73.6 million compared to net loss of USD 124.01 million a year ago. Basic earnings per share from continuing operations was USD 0.54 compared to basic loss per share from continuing operations of USD 1.01 a year ago. Diluted earnings per share from continuing operations was USD 0.52 compared to diluted loss per share from continuing operations of USD 1.01 a year ago.